Skip to content
ApprovedFDA approved

Mirabegron (Myrbetriq)

Prescription medicine for overactive bladder that is also studied for fat burning, but is not approved for that.

Mirabegron (Myrbetriq) vial

DETAILED OVERVIEW

What is Mirabegron (Myrbetriq)?

Mirabegron (Myrbetriq) is a prescription medicine approved for the symptoms of overactive bladder: in the United States since 2012, and in Europe under the name Betmiga. It acts on a receptor that relaxes the muscle of the bladder and, in brown fat (the body's heat-producing fat), switches on heat production. For this reason it is also studied for fat burning, and it is used off-label.

In studies in healthy adults it switched on the activity of brown fat, and after longer treatment the amount of brown fat and insulin sensitivity increased. Its main risk is strain on the heart and blood vessels: it can raise blood pressure and heart rate. The official prescribing information warns of severe blood pressure rises and a fast heartbeat. It is contraindicated in severe, uncontrolled high blood pressure. It can cause difficulty passing urine and, rarely, severe swelling of the face, lips or tongue. It is not recommended in pregnancy and breastfeeding. WADA does not ban it outright, but several national sports federations treat it as a monitored substance.

Mechanism

Selective β3-adrenoceptor agonist (detrusor + BAT UCP1 induction)

Half-life

~50 hours (once-daily dosing optimal)

Onset time

Detrusor 2-4 h; BAT activation chronic dose 2-4 weeks

Legal status

FDA + EMA Rx (OAB), HU + PL registered. WADA: not explicitly banned, monitored by some national federations.

Data console

Lab data

Androgenic:AnabolicN/A (not an AAS)
AR bindingβ3-adrenoceptor Ki ~5-10 nM; β1/β2-receptor >50x lower…
Active half-life~50 hours
Detection windowWADA-accredited LC-MS/MS urine detection ~3-5 days (Mirabegron + N-dealkyl-Mirabegron metabolite). National federation monitoring thresholds vary.
AromatizationDoes not aromatize (not a steroid – selective β3-adrenoceptor agonist). No CYP19 interaction; the estrogen axis is unaffected.
HepatotoxicityLow – DILI is rare, ALT elevation <2% incidence documented in clinical trials (Khullar 2013 OAB-RCT PMID 23537815). CYP2D6 + CYP3A4 metabolism creates drug-interaction risk with metoprolol and desipramine (Mirabegron is a CYP2D6 substrate-inhibitor, plasma-level elevator).

Safety

Side effects, stop signs, contraindications

Side effects · 8

  • Blood pressure elevation, hypertension (dose-dependent, one of the most common and clinically important effects; pre-existing hypertension can worsen)
  • Tachycardia, increased resting heart rate, palpitations
  • Urinary retention, difficulty voiding, urinary tract infection (from detrusor relaxation, especially with bladder outlet obstruction)
  • Headache, dizziness
  • Nasopharyngitis, upper respiratory symptoms, dry mouth
  • Constipation, nausea, abdominal discomfort
  • QTc prolongation at higher doses (ECG monitoring warranted, especially with other QT-prolonging drugs)
  • Rare but serious: angioedema (swelling of face, lips, tongue, larynx, with airway-obstruction risk – requires immediate discontinuation)

Contraindications · 7

  • Severe, uncontrolled hypertension (>=180/110 mmHg) – absolute contraindication (FDA warning; do not start if blood pressure is uncontrolled)
  • Severe renal impairment (ESRD/dialysis) and severe hepatic impairment (Child-Pugh C) – not recommended; dose reduction required in moderate impairment
  • Clinically significant bladder outlet obstruction or OAB treated with antimuscarinics – increased urinary retention risk
  • Pre-existing tachyarrhythmia, unstable/significant cardiac disease, or known QT prolongation / QT-prolonging drugs – elevated cardiac risk
  • Pregnancy and breastfeeding – not recommended (insufficient human safety data)
  • Hypersensitivity to mirabegron or excipients, or prior history of angioedema
  • Caution with sensitive CYP2D6 substrates (e.g. metoprolol, desipramine) and CYP2D6-inhibiting SSRIs/TCAs – plasma-level increase, dose adjustment may be needed

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about Mirabegron (Myrbetriq)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.